{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:34:11Z","timestamp":1780630451520,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00228-018-2541-2","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T13:40:46Z","timestamp":1534426846000},"page":"1273-1279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Optimal sampling time and clinical implication of the SCN5A promoter haplotype in propafenone therapeutic drug monitoring"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2497-0063","authenticated-orcid":false,"given":"Kosuke","family":"Doki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Aonuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinao","family":"Kohda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,16]]},"reference":[{"key":"2541_CR1","doi-asserted-by":"publisher","first-page":"21S","DOI":"10.1046\/j.1365-2125.2001.00768.x","volume":"52","author":"TJ Campbell","year":"2001","unstructured":"Campbell TJ, Williams KM (2001) Therapeutic drug monitoring: antiarrhythmic drugs. Br J Clin Pharmacol 52:21S\u201334S","journal-title":"Br J Clin Pharmacol"},{"key":"2541_CR2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2165\/00003088-200342070-00004","volume":"42","author":"G J\u00fcrgens","year":"2003","unstructured":"J\u00fcrgens G, Graudal NA, Kampmann JP (2003) Therapeutic drug monitoring of antiarrhythmic drugs. Clin Pharmacokinet 42:647\u2013663","journal-title":"Clin Pharmacokinet"},{"key":"2541_CR3","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1253\/circj.CJ-66-0138","volume":"81","author":"K Aonuma","year":"2017","unstructured":"Aonuma K, Shiga T, Atarashi H, Doki K, Echizen H, Hagiwara N, Hasegawa J, Hayashi H, Hirao K, Ichida F, Ikeda T, Maeda Y, Matsumoto N, Sakaeda T, Shimizu W, Sugawara M, Totsuka K, Tsuchishita Y, Ueno K, Watanabe E, Hashiguchi M, Hirata S, Kasai H, Matsumoto Y, Nogami A, Sekiguchi Y, Shinohara T, Sugiyama A, Sumitomo N, Suzuki A, Takahashi N, Yukawa E, Homma M, Horie M, Inoue H, Ito H, Miura T, Ohe T, Shinozaki K, Tanaka K, on behalf of the Japanese Circulation Society and the Japanese Society of Therapeutic Drug Monitoring Joint Working Group (2017) Guidelines for therapeutic drug monitoring of cardiovascular drugs clinical use of blood drug concentration monitoring (JCS 2015 - digest version). Circ J 81:581\u2013612. https:\/\/doi.org\/10.1253\/circj.CJ-66-0138","journal-title":"Circ J"},{"key":"2541_CR4","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2165\/00003495-199550020-00005","volume":"50","author":"AG Kishore","year":"1995","unstructured":"Kishore AG, Camm AJ (1995) Guidelines for the use of propafenone in treating supraventricular arrhythmias. Drugs 50:250\u2013262","journal-title":"Drugs"},{"key":"2541_CR5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S0002-9149(96)00332-3","volume":"78","author":"PJ Podrid","year":"1996","unstructured":"Podrid PJ, Anderson JL (1996) Safety and tolerability of long-term propafenone therapy for supraventricular tachy-arrhythmias. The Propafenone multicenter study group. Am J Cardiol 78:430\u2013434","journal-title":"Am J Cardiol"},{"key":"2541_CR6","doi-asserted-by":"publisher","first-page":"59N","DOI":"10.1016\/S0002-9149(98)00739-5","volume":"82","author":"AP Rae","year":"1998","unstructured":"Rae AP (1998) Placebo-controlled evaluations of propafenone for atrial tachy-arrhythmias. Am J Cardiol 82:59N\u201365N","journal-title":"Am J Cardiol"},{"key":"2541_CR7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0026-895X(25)12836-8","volume":"40","author":"HK Kroemer","year":"1991","unstructured":"Kroemer HK, Fischer C, Meese CO, Eichelbaum M (1991) Enantiomer\/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism. Mol Pharmacol 40:135\u2013142","journal-title":"Mol Pharmacol"},{"key":"2541_CR8","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/elps.200500664","volume":"27","author":"M Afshar","year":"2006","unstructured":"Afshar M, Thormann W (2006) Capillary electrophoretic investigation of the enantioselective metabolism of propafenone by human cytochrome P-450 SUPERSOMES: evidence for atypical kinetics by CYP2D6 and CYP3A4. Electrophoresis 27:1526\u20131536","journal-title":"Electrophoresis"},{"key":"2541_CR9","first-page":"1489","volume":"34","author":"G Philipsborn von","year":"1984","unstructured":"von Philipsborn G, Gries J, Hofmann HP, Kreiskott H, Kretzschmar R, M\u00fcller CD, Raschack M, Teschendorf HJ (1984) Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone. Arzneimittelforschung 34:1489\u20131497","journal-title":"Arzneimittelforschung"},{"key":"2541_CR10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0022-3565(25)22060-2","volume":"246","author":"G Malfatto","year":"1988","unstructured":"Malfatto G, Zaza A, Forster M, Sodowick B, Danilo P Jr, Rosen MR (1988) Electrophysiologic, inotropic and antiarrhythmic effects of propafenone, 5-hydroxypropafenone and N-depropylpropafenone. J Pharmacol Exp Ther 246:419\u2013426","journal-title":"J Pharmacol Exp Ther"},{"key":"2541_CR11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.CIR.75.4.785","volume":"75","author":"LA Siddoway","year":"1987","unstructured":"Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, Woosley RL (1987) Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 75:785\u2013791","journal-title":"Circulation"},{"key":"2541_CR12","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/oxfordjournals.eurheartj.a059934","volume":"12","author":"G Steurer","year":"1991","unstructured":"Steurer G, Weber H, Schmidinger H, Plass H, Frey B, P\u00fcrerfellner H, Probst P (1991) Plasma propafenone concentration in the evaluation of anti-arrhythmic efficacy. Eur Heart J 12:526\u2013532","journal-title":"Eur Heart J"},{"key":"2541_CR13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.105.580811","volume":"113","author":"CR Bezzina","year":"2006","unstructured":"Bezzina CR, Shimizu W, Yang P, Koopmann TT, Tanck MW, Miyamoto Y, Kamakura S, Roden DM, Wilde AA (2006) Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation 113:338\u2013344","journal-title":"Circulation"},{"key":"2541_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/FPC.0b013e328361fb8d","volume":"23","author":"K Doki","year":"2013","unstructured":"Doki K, Homma M, Kuga K, Aonuma K, Kohda Y (2013) SCN5A promoter haplotype affects the therapeutic range for serum flecainide concentration in Asian patients. Pharmacogenet Genomics 23:349\u2013354","journal-title":"Pharmacogenet Genomics"},{"key":"2541_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4099","volume":"32","author":"Y Shirayama","year":"2018","unstructured":"Shirayama Y, Doki K, Sekiguchi Y, Aonuma K, Kohda Y, Homma M (2018) Simultaneous determination of serum propafenone and its metabolites using high-performance liquid chromatography. Biomed Chromatogr 32:e4099","journal-title":"Biomed Chromatogr"},{"key":"2541_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1161\/01.CIR.68.3.589","volume":"68","author":"SJ Connolly","year":"1983","unstructured":"Connolly SJ, Kates RE, Lebsack CS, Harrison DC, Winkle RA (1983) Clinical pharmacology of propafenone. Circulation 68:589\u2013596","journal-title":"Circulation"},{"key":"2541_CR17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/clpt.1989.69","volume":"45","author":"RG Zoble","year":"1989","unstructured":"Zoble RG, Kirsten EB, Brewington J (1989) Pharmacokinetic and pharmacodynamics evaluation of propafenone in patients with ventricular arrhythmia. Propafenone Research Group. Clin Pharmacol Ther 45:535\u2013541","journal-title":"Clin Pharmacol Ther"},{"key":"2541_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/BF00608213","volume":"30","author":"L Frabetti","year":"1986","unstructured":"Frabetti L, Marchesini B, Capucci A, Cavallini C, Gubelli S, Ambrosioni E, Magnani B (1986) Antiarrhythmic efficacy of propafenone: evaluation of effective plasma levels following single and multiple doses. Eur J Clin Pharmacol 30:665\u2013671","journal-title":"Eur J Clin Pharmacol"},{"key":"2541_CR19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1365-2125.1987.tb03109.x","volume":"23","author":"JE Axelson","year":"1987","unstructured":"Axelson JE, Chan GL, Kirsten EB, Mason WD, Lanman RC, Kerr CR (1987) Food increases the bioavailability of propafenone. Br J Clin Pharmacol 23:735\u2013741","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2541-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2541-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2541-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T10:55:38Z","timestamp":1751799338000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2541-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,16]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["2541"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2541-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,16]]},"assertion":[{"value":"9 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethical committee of the University of Tsukuba (approval number, 63-2). Written informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}